Intra-Cellular Therapies (NASDAQ:ITCI) Coverage Initiated by Analysts at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) in a research report issued to clients and investors on Thursday. The firm set a "hold" rating on the biopharmaceutical company's stock.

Other analysts have also recently issued reports about the stock. Piper Sandler reissued a "neutral" rating and set a $132.00 price target (up from $107.00) on shares of Intra-Cellular Therapies in a research note on Tuesday, January 14th. Canaccord Genuity Group lowered Intra-Cellular Therapies from a "buy" rating to a "hold" rating and increased their price objective for the company from $119.00 to $132.00 in a research report on Friday, January 31st. Royal Bank of Canada restated a "sector perform" rating and set a $132.00 target price (up previously from $108.00) on shares of Intra-Cellular Therapies in a research report on Wednesday, January 22nd. Leerink Partnrs cut Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a report on Monday, January 13th. Finally, Baird R W lowered Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research report on Monday, January 13th. Ten research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $106.08.

Remove Ads

Intra-Cellular Therapies Stock Up 0.0 %

ITCI traded up $0.05 during trading on Thursday, hitting $131.65. The company's stock had a trading volume of 1,836,929 shares, compared to its average volume of 1,339,146. The stock has a market capitalization of $14.00 billion, a price-to-earnings ratio of -151.32 and a beta of 0.69. The firm's 50 day moving average price is $128.61 and its two-hundred day moving average price is $97.59. Intra-Cellular Therapies has a 12 month low of $64.09 and a 12 month high of $131.67.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last released its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The business had revenue of $199.22 million during the quarter, compared to the consensus estimate of $205.08 million. On average, sell-side analysts forecast that Intra-Cellular Therapies will post -0.64 earnings per share for the current year.

Institutional Investors Weigh In On Intra-Cellular Therapies

Several large investors have recently bought and sold shares of the company. Norges Bank acquired a new position in shares of Intra-Cellular Therapies in the 4th quarter valued at $268,347,000. Raymond James Financial Inc. acquired a new position in Intra-Cellular Therapies in the fourth quarter valued at about $76,451,000. Adage Capital Partners GP L.L.C. increased its holdings in shares of Intra-Cellular Therapies by 266.5% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 678,000 shares of the biopharmaceutical company's stock worth $56,627,000 after acquiring an additional 493,000 shares in the last quarter. TimesSquare Capital Management LLC raised its position in shares of Intra-Cellular Therapies by 91.8% during the fourth quarter. TimesSquare Capital Management LLC now owns 840,269 shares of the biopharmaceutical company's stock worth $70,179,000 after purchasing an additional 402,186 shares during the period. Finally, Deep Track Capital LP raised its position in shares of Intra-Cellular Therapies by 24.9% during the fourth quarter. Deep Track Capital LP now owns 2,000,000 shares of the biopharmaceutical company's stock worth $167,040,000 after purchasing an additional 399,307 shares during the period. Institutional investors own 92.33% of the company's stock.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.